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Despite advances in chemotherapeutic protocols and autologous hematopoietic stem-cell transplantation, multiple myeloma (MM) remains incurable largely due to disease recurrence. Novel strategies towards maintaining tumor regression are therefore urgently needed. CD138 (Syndecan-1) expression is a well-recognized hallmark of MM cells, with high serum levels an indicator of poor prognosis. Within the hematopoietic compartment, this antigen is localized only to plasma and MM cells. To date, this tumor-associated antigen has been targeted using a drug-conjugated monoclonal antibody (BT-062, BioTest, phase 2 trial, NCT01001442). The biologic potential of many antibody-based therapies is degraded due to diminished access of tumor deposits and inability to complete a therapeutic effect. T-cell therapies circumvent these limitations as they can migrate from the blood stream through tissues with high interstitial pressures and can proliferate in situ to achieve an effective effector-to-target cell ratio. To evaluate the effi cacy of immunotherapy infusing T cells genetically modifi ed to express a chimeric antigen receptor (CAR) , we have leveraged our current platform technology that is used to manufacture CD19-specifi c T cells to now generate CD138-specfi c T cells. The electro-transfer of Sleeping Beauty system followed by co-culture on CD138 + artifi cial antigen presenting cells resulted in the selective outgrowth of CAR + T cells. Analysis using MM cell lines revealed specifi c functional recognition of our CAR to CD138 + cells) while sparing CD138 neg non-expressors. We are further characterizing our approach using single-cell gene profi ling technologies to fi ne tune the cell product for human application. Our CD138-specifi c CAR + T cells should complement conventional chemotherapies and fi ll unmet needs for more potent immunotherapeutic agent against relapsed/refractory MM.
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Although replication-competent viruses have been developed to treat cancers, their cytotoxic effects are insuffi cient due to infection inhibited by generation of neutralizing antibodies and systemic administration is diffi cult due to life-threatening serious side effects of virus-induced cytokine surge. A replication-competent virus-infected carrier cell overcomes virus-induced immunogenicity and induces complete tumor reduction. This carrier cell system has associated problems, including diffi culties of systemic administration as a result of trapping in capillary vessels and the need for hospitalization and an isolated room as a result of the biodiversity treaty. To overcome these critical problems, we devised a plasmid/polycation/polyanion complex and assessed the potential of ternary plasmid complexes coated with chondroitin sulfate in gene therapy for ovarian cancer. The transfection effi ciencies and the antitumor effects of chondroitin sulfate-coated complex as an anionic component were compared to those of hyaluronic acid on ovarian cancer. Plasmid harboring the gene of murine granulocyte macrophage-colony stimulating factor (mGM-CSF) was complexed with polyethyleneimine (PEI) and hyaluronic acid (HA) or chondroitin sulfate (CS). Murine OVHM cells were injected into (C57BL/6 × C3H/He) F1 mice to prepare a subcutaneous or intraperitoneal tumor model. DNA/PEI was charged positively and DNA/PEI/CS or DNA/PEI/HA was charged negatively. Although binary DNA/PEI aggregated red blood cells, ternary DNA/ PEI/CS did not. Plasmid-green fl uorescent protein (GFP)/PEI coated with 10-kilodalton CS increased transfection effi ciency compared to coating with CS of higher-molecular-weight and HA. The size of DNA/PEI/10-kilodalton CS was 79 nm, which is 65% of that of DNA/ S240 CANCER -IMMUNOTHERAPY III PEI/HA at 122 nm. The transfection effi ciency of binary GFP/PEI did not yield signifi cant differences in between normal and cancer cells but that of GFP/PEI/10-kilodalton CS in ovarian cancer cells was 6 times that in normal cells. Binary complex was more toxic than ternary complexes. GFP expression by ternary GFP/PEI/10kilodalton CS transfection peaked at days 2 or 3 and persisted for 9-27 days in cancer cells. Intraperitoneal injection of mGM-CSF/ PEI coated with 10-kilodalton CS prolonged survival compared to that coated with HA. Intratumoral injection of mGM-CSF/PEI coated with 10-kilodalton CS achieved 100% rates of mouse survival but that with HA did not. These fi ndings suggest that GM-CSF/PEI coated with 10-kilodalton CS has potential for use in gene therapy of ovarian cancer. Background The receptor tyrosine kinase EphA2 is overexpressed in several types of cancers and is currently being pursued as a target for breast cancer therapeutics. The EphA2 ligand EphrinA1 induces EphA2 phosphorylation and intracellular internalization and degradation, thus inhibiting tumor progression. The hematopoietic growth factor, FMS-like tyrosine kinase receptor ligand (Flt3L), promotes expansion and mobilization of functional dendritic cells. Methods We tested the EphrinA1-EphA2 interaction in MDA-MB-231 breast cancer cells focusing on the receptor-ligand mediated apoptosis of breast cancer cells. In order to determine whether the EphrinA1-EphA2 interaction-associated apoptosis and Flt3L-mediated immunotherapy would have an additive effect in inhibiting tumor growth, we used an immunocompetent mouse model of breast cancer to evaluate intratumoral (i.t.) inoculation strategies with human adenovirus (HAd) vectors expressing either EphrinA1 (HAd-EphrinA1-Fc), Flt3L (HAd-Flt3L) or a combination of EphrinA1-Fc + Flt3L (HAd-EphrinA1-Fc + HAd-Flt3L). Results In vitro analysis demonstrated that an EphrinA1-EphA2 interaction led to apoptosis-related changes in breast cancer cells. In vivo, three i.t. inoculations of HAd-EphrinA1-Fc showed potent inhibition of tumor growth. Furthermore, increased inhibition in tumor growth was observed with the combination of HAd-EphrinA1-Fc and HAd-Flt3L accompanied by the generation of an anti-tumor adaptive immune response. Conclusions The results indicating induction of apoptosis and inhibition of mammary tumor growth show the potential therapeutic benefi ts of HAd-EphrinA1-Fc. In combination with HAd-Flt3L, this represents a promising strategy to effectively induce mammary tumor regression by HAd vector-based therapy. Adoptive immunotherapy using Chimeric Antigen Receptor (CAR)-gene modifi ed T cells is a promising strategy to treat patients suffering from autoimmune diseases and malignancies. The CARs can recognize target antigens in a HLA independent manner, therefore, CAR-gene modifi ed T cell therapy is applicable to a wide range of patients regardless of HLA types. The basic CARs consist of scFv from a monoclonal antibody, an extracellular hinge region, a transmembrane domain, and an intracellular signaling domain. To improve the effi cacy of CAR-gene modifi ed T cells, optimization of signaling domains incorporated in CAR constructs are important issues. The fi rst-generation CARs have the intracellular domain (ICD) of CD3z, while the second-generation CARs have additional ICDs from various co-stimulatory protein receptors (e.g. CD28, 41BB, ICOS) which are expected to enhance antitumor activities and survival of T cells. Recently, the third-generation CARs have been developed by incorporating multiple signaling domains to augment T cell signaling capacity. Glucocorticoid-induced TNF-receptor (GITR), a member of the TNF receptor superfamily, is known to inhibit the suppressive activity of regulatory T cells and extend the survival of T-lymphocytes. In this study, we have developed novel second and third generation CARs incorporated GITR ICD as a co-stimulatory molecule for purpose of T cell survival prolongation and inhibition of regulatory T cells' suppressive activity. We have found the position of GITR ICD incorporated in CAR constructs were crucial for proper expression of CARs. To optimize the CAR design of our novel vectors, we have also designed and constructed a variety of vectors to express anti-CEA and anti-EGFR CARs having different leader sequences and hinge sequences with and without additional ICDs of co-stimulatory molecules, and evaluated the expression of CARs and their biological activities, and could develop the optimized promising CAR vector constructs. Our novel second and third generation CARs containing GITR ICD were highly expressed on the T cells and showed antigen specifi c cytokine secretion and cytotoxic activities against tumor cells. T cells expressing our novel CARs may be promising in adoptive cancer immunotherapy. Background: Our previous work has included the development of viral vectors where transgene expression is controlled by the transcriptional functions of the p53 tumor suppressor protein. Since wild-type p53 is frequently maintained in melanoma, we propose that such vectors may provide an opportunity for interplay between endogenous and exogenous factors. Transfer of p19Arf, a functional partner of p53, should help activate endogenous p53, thus supporting both vector expression and killing of tumor cells. Interferon-beta (IFN) is known to activate the immune system, induce apoptosis and inhibit angiogenesis. Moreover, interactions of the p53/Arf and IFN pathways have been reported. Previously we have shown that combined, but not individual, transfer of p19Arf and IFN mediated by our p53-responsive Ad5 vector induced massive cell death of B16 (mouse melanoma) both in vitro and in vivo. Objective: Our current aims include revealing involvement of the immune system in response to gene transfer protocols utilizing p53-responsive Ad5 or AdRGD vectors. Methods/Results: B16 cells with forced expression of CAR were transduced ex vivo with the Ad5 vectors (called AdPG) and implanted subcutaneously in C57BL/6 mice. Seven days later, these same mice received a challenge with fresh
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